+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibodies Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 250 Pages
  • May 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5972681
Description Jump to:
The global antibody contract manufacturing market is poised for significant growth over the next decade, with projections indicating the market will reach a valuation of approximately $13.6 billion by 2031, up from $6.3 billion in 2024. This growth is driven by a compound annual growth rate (CAGR) of 11.6%, as detailed in a recent report.

Market Overview and Growth Drivers

The antibody contract manufacturing market, valued at $4.8 billion in 2022, has seen steady growth due to the increasing demand for biopharmaceuticals. The sector recorded a historic CAGR of 9.6% from 2016 to 2022, and this upward trend is expected to continue. The growing prevalence of chronic and infectious diseases, along with advancements in biotechnology, are key factors contributing to this market expansion.

Monoclonal Antibodies Lead the Charge

Monoclonal antibodies (mAbs) are projected to dominate the market, with an estimated market value of around $15.9 billion by 2033. These antibodies, known for their specificity and efficacy in treating a range of diseases, including cancer and autoimmune disorders, are integral to the biopharmaceutical industry. Their production involves a standardized process that ensures consistency and quality, making them a preferred choice for contract manufacturing.

End-to-End Continuous Manufacturing

One of the significant trends shaping the market is the development of end-to-end continuous manufacturing processes. This approach promises to revolutionize biologics production by reducing manufacturing time, cutting costs, and minimizing contamination risks. Continuous production methods are gaining traction, with real-time quality monitoring ensuring high reliability in the final products. Despite the initial high investment costs and complexity, continuous manufacturing is expected to offer substantial long-term benefits.

Regional Insights

United States: A Hub of Innovation

The U.S. holds a commanding share of the North American market, accounting for approximately 89.4% in 2022. The country's advanced healthcare infrastructure, coupled with a robust pipeline of clinical trials and strong government support for biologics, drives market growth. The rapid development and approval of antibody drugs, particularly during the COVID-19 pandemic, have further bolstered the market.

United Kingdom: Leading in Research and Development

The U.K. captured around 26.7% of the European market in 2022, thanks to significant investments in research and development for infectious diseases. The country's strong regulatory framework and public sector funding are key factors supporting market growth. The U.K. continues to play a crucial role in global efforts to combat neglected and infectious diseases through innovative antibody therapies.

South Korea: A Rising Star

South Korea emerged as a prominent player in the East Asian market, holding about 70.6% market share in 2022. The country's commitment to biopharmaceutical manufacturing excellence, highlighted by events like the Biologics Manufacturing Korea conference, positions it as a key hub for antibody contract manufacturing. Recognitions such as the Korea Bioprocessing Excellence Award underscore South Korea's capabilities in this sector.

Market Segmentation

Product and Expression Systems

Monoclonal antibodies dominate the product segment, holding approximately 89.1% of the market share in 2022. The mammalian expression system is the most widely adopted, accounting for about 84.4% of the market. This system's ability to produce complex proteins with post-translational modifications similar to those in humans makes it the preferred choice for biopharmaceutical production.

Company Size and Scale of Operations

Mid-sized companies represented around 46.2% of the market in 2022. These companies are increasingly driving innovation and approvals for new drugs, despite often lacking in-house manufacturing capabilities. The commercial scale of operations held a share of about 54.4%, driven by the high incidence of chronic diseases and the growing need for contract manufacturing to meet global demand.

Competitive Landscape

The antibody contract manufacturing market is characterized by significant consolidation as major players pursue mergers and acquisitions to enhance their capabilities. Notable developments include:

  • AMRI's Acquisition: In June 2017, AMRI was acquired in a deal valued at over $920 million, reflecting the active M&A market for contract manufacturers.
  • AGC Biologics and Ono Pharmaceutical Partnership: In August 2020, AGC Biologics partnered with Ono Pharmaceutical Co., Ltd. to develop innovative biopharmaceuticals, showcasing the industry's collaborative efforts to advance drug development.

Key Market Players Include

  • AMRI
  • AGC Biologics
  • Aldevron
  • Eurofins CDMO
  • Boehringer Ingelheim BioXcellence
  • FUJIFILM Diosynth Biotechnologies
  • Emergent BioSolutions
  • KBI Biopharma
  • Lonza
  • Novasep
  • Nitto Avecia Pharma Services
  • Pierre Fabre
  • Samsung BioLogics
  • Synthon
  • Thermo Fisher Scientific
  • AbbVie, Inc.

Global Antibodies Contract Manufacturing Market Segmentation

By Product:

  • Monoclonal Antibodies
  • Antibody Fragments
  • Polyclonal Antibodies

By Expression System:

  • Mammalian
  • Microbial
  • Bacteria
  • Yeast

By Company Size:

  • Small
  • Mid-sized
  • Large
  • Very large

By Scale of Operation:

  • Preclinical
  • Clinical
  • Commercial

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Antibodies Contract Manufacturing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Product Adoption/Usage Analysis
2.4. List of Trading Companies
2.5. List of Local Manufacturers and their Distribution Strategy/Locations
2.6. Key Regulatory Scenario
2.7. Value Chain Analysis
2.8. Porter’s Five Forces Analysis
2.9. COVID-19 Impact Analysis
2.9.1. Supply
2.9.2. Demand
2.10. Economic Overview
2.10.1. World Economic Projections 2.11.PESTLE Analysis
3. Global Antibodies Contract Manufacturing Market Outlook, 2018 - 2031
3.1. Global Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Monoclonal Antibodies
3.1.1.2. Antibody Fragments
3.1.1.3. Polyclonal Antibodies
3.2. Global Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Mammalian
3.2.1.2. Microbial
3.2.1.2.1. Bacteria
3.2.1.2.2. Yeast
3.3. Global Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Small
3.3.1.2. Mid-sized
3.3.1.3. Large
3.3.1.4. Very large
3.4. Global Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Preclinical
3.4.1.2. Clinical
3.4.1.3. Commercial
3.5. Global Antibodies Contract Manufacturing Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Antibodies Contract Manufacturing Market Outlook, 2018 - 2031
4.1. North America Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Monoclonal Antibodies
4.1.1.2. Antibody Fragments
4.1.1.3. Polyclonal Antibodies
4.2. North America Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Mammalian
4.2.1.2. Microbial
4.2.1.2.1. Bacteria
4.2.1.2.2. Yeast
4.3. North America Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Small
4.3.1.2. Mid-sized
4.3.1.3. Large
4.3.1.4. Very large
4.4. North America Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Preclinical
4.4.1.2. Clinical
4.4.1.3. Commercial
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
4.5.1.2. U.S. Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
4.5.1.3. U.S. Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
4.5.1.4. U.S. Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
4.5.1.5. Canada Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
4.5.1.6. Canada Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
4.5.1.7. Canada Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
4.5.1.8. Canada Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Antibodies Contract Manufacturing Market Outlook, 2018 - 2031
5.1. Europe Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Monoclonal Antibodies
5.1.1.2. Antibody Fragments
5.1.1.3. Polyclonal Antibodies
5.2. Europe Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Mammalian
5.2.1.2. Microbial
5.2.1.2.1. Bacteria
5.2.1.2.2. Yeast
5.3. Europe Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Small
5.3.1.2. Mid-sized
5.3.1.3. Large
5.3.1.4. Very large
5.4. Europe Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Preclinical
5.4.1.2. Clinical
5.4.1.3. Commercial
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Germany Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
5.5.1.2. Germany Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
5.5.1.3. Germany Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
5.5.1.4. Germany Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.5.1.5. U.K. Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
5.5.1.6. U.K. Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
5.5.1.7. U.K. Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
5.5.1.8. U.K. Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.5.1.9. France Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
5.5.1.10. France Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
5.5.1.11. France Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
5.5.1.12. France Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.5.1.13. Italy Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
5.5.1.14. Italy Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
5.5.1.15. Italy Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
5.5.1.16. Italy Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.5.1.17. Turkey Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
5.5.1.18. Turkey Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
5.5.1.19. Turkey Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
5.5.1.20. Turkey Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.5.1.21. Russia Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
5.5.1.22. Russia Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
5.5.1.23. Russia Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
5.5.1.24. Russia Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.5.1.25. Rest of Europe Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
5.5.1.26. Rest of Europe Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
5.5.1.27. Rest of Europe Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
5.5.1.28. Rest of Europe Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Antibodies Contract Manufacturing Market Outlook, 2018 - 2031
6.1. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Monoclonal Antibodies
6.1.1.2. Antibody Fragments
6.1.1.3. Polyclonal Antibodies
6.2. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Mammalian
6.2.1.2. Microbial
6.2.1.2.1. Bacteria
6.2.1.2.2. Yeast
6.3. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Small
6.3.1.2. Mid-sized
6.3.1.3. Large
6.3.1.4. Very large
6.4. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Preclinical
6.4.1.2. Clinical
6.4.1.3. Commercial
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. China Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
6.5.1.2. China Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
6.5.1.3. China Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
6.5.1.4. China Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.5.1.5. Japan Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
6.5.1.6. Japan Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
6.5.1.7. Japan Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
6.5.1.8. Japan Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.5.1.9. South Korea Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
6.5.1.10. South Korea Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
6.5.1.11. South Korea Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
6.5.1.12. South Korea Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.5.1.13. India Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
6.5.1.14. India Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
6.5.1.15. India Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
6.5.1.16. India Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.5.1.17. Southeast Asia Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
6.5.1.18. Southeast Asia Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
6.5.1.19. Southeast Asia Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
6.5.1.20. Southeast Asia Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.5.1.21. Rest of Asia Pacific Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
6.5.1.22. Rest of Asia Pacific Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
6.5.1.23. Rest of Asia Pacific Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
6.5.1.24. Rest of Asia Pacific Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Antibodies Contract Manufacturing Market Outlook, 2018 - 2031
7.1. Latin America Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Monoclonal Antibodies
7.1.1.2. Antibody Fragments
7.1.1.3. Polyclonal Antibodies
7.2. Latin America Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Mammalian
7.2.1.2. Microbial
7.2.1.2.1. Bacteria
7.2.1.2.2. Yeast
7.3. Latin America Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Small
7.3.1.2. Mid-sized
7.3.1.3. Large
7.3.1.4. Very large
7.4. Latin America Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Preclinical
7.4.1.2. Clinical
7.4.1.3. Commercial
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
7.5.1.2. Brazil Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
7.5.1.3. Brazil Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
7.5.1.4. Brazil Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.5.1.5. Mexico Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
7.5.1.6. Mexico Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
7.5.1.7. Mexico Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
7.5.1.8. Mexico Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.5.1.9. Argentina Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
7.5.1.10. Argentina Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
7.5.1.11. Argentina Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
7.5.1.12. Argentina Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.5.1.13. Rest of Latin America Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
7.5.1.14. Rest of Latin America Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
7.5.1.15. Rest of Latin America Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
7.5.1.16. Rest of Latin America Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, 2018 - 2031
8.1. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Monoclonal Antibodies
8.1.1.2. Antibody Fragments
8.1.1.3. Polyclonal Antibodies
8.2. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Mammalian
8.2.1.2. Microbial
8.2.1.2.1. Bacteria
8.2.1.2.2. Yeast
8.3. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Small
8.3.1.2. Mid-sized
8.3.1.3. Large
8.3.1.4. Very large
8.4. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Preclinical
8.4.1.2. Clinical
8.4.1.3. Commercial
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. GCC Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
8.5.1.2. GCC Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
8.5.1.3. GCC Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
8.5.1.4. GCC Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.5.1.5. South Africa Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
8.5.1.6. South Africa Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
8.5.1.7. South Africa Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
8.5.1.8. South Africa Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.5.1.9. Egypt Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
8.5.1.10. Egypt Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
8.5.1.11. Egypt Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
8.5.1.12. Egypt Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.5.1.13. Nigeria Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
8.5.1.14. Nigeria Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
8.5.1.15. Nigeria Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
8.5.1.16. Nigeria Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.5.1.17. Rest of Middle East & Africa Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
8.5.1.18. Rest of Middle East & Africa Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
8.5.1.19. Rest of Middle East & Africa Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
8.5.1.20. Rest of Middle East & Africa Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis, 2023
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. AMRI
9.3.1.1. Company Overview
9.3.1.2. Product Portfolio
9.3.1.3. Financial Overview
9.3.1.4. Business Strategies and Development
9.3.2. AGC Biologics
9.3.2.1. Company Overview
9.3.2.2. Product Portfolio
9.3.2.3. Financial Overview
9.3.2.4. Business Strategies and Development
9.3.3. Aldevron
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Financial Overview
9.3.3.4. Business Strategies and Development
9.3.4. Eurofins CDMO
9.3.4.1. Company Overview
9.3.4.2. Product Portfolio
9.3.4.3. Financial Overview
9.3.4.4. Business Strategies and Development
9.3.5. Boehringer Ingelheim BioXcellence
9.3.5.1. Company Overview
9.3.5.2. Product Portfolio
9.3.5.3. Financial Overview
9.3.5.4. Business Strategies and Development
9.3.6. FUJIFILM Diosynth Biotechnologies
9.3.6.1. Company Overview
9.3.6.2. Product Portfolio
9.3.6.3. Financial Overview
9.3.6.4. Business Strategies and Development
9.3.7. Emergent BioSolutions
9.3.7.1. Company Overview
9.3.7.2. Product Portfolio
9.3.7.3. Financial Overview
9.3.7.4. Business Strategies and Development
9.3.8. KBI Biopharma
9.3.8.1. Company Overview
9.3.8.2. Product Portfolio
9.3.8.3. Financial Overview
9.3.8.4. Business Strategies and Development
9.3.9. Pierre Fabre
9.3.9.1. Company Overview
9.3.9.2. Product Portfolio
9.3.9.3. Financial Overview
9.3.9.4. Business Strategies and Development
9.3.10. Lonza
9.3.10.1. Company Overview
9.3.10.2. Product Portfolio
9.3.10.3. Financial Overview
9.3.10.4. Business Strategies and Development
9.3.11. Novasep
9.3.11.1. Company Overview
9.3.11.2. Product Portfolio
9.3.11.3. Financial Overview
9.3.11.4. Business Strategies and Development
9.3.12. Nitto Avecia Pharma Services
9.3.12.1. Company Overview
9.3.12.2. Product Portfolio
9.3.12.3. Financial Overview
9.3.12.4. Business Strategies and Development
10. Appendix
10.1.Research Methodology
10.2.Report Assumptions
10.3.Acronyms and Abbreviations

Companies Mentioned

  • AMRI
  • AGC Biologics
  • Aldevron
  • Eurofins CDMO
  • Boehringer Ingelheim BioXcellence
  • FUJIFILM Diosynth Biotechnologies
  • Emergent BioSolutions
  • KBI Biopharma
  • Lonza
  • Novasep
  • Nitto Avecia Pharma Services
  • Pierre Fabre
  • Samsung BioLogics
  • Synthon
  • Thermo Fisher Scientific
  • AbbVie, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Next Generation Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Next Generation Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 106 Pages
  • Global
Antibodies Contract Manufacturing Market by Antibody Type, Source, Services, End-User - Global Forecast 2025-2030 - Product Image

Antibodies Contract Manufacturing Market by Antibody Type, Source, Services, End-User - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Research Antibodies and Reagents Global Market Report 2024 - Product Image

Research Antibodies and Reagents Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Monoclonal Antibody Collaboration and Licensing Deals 2016-2024 - Product Image

Monoclonal Antibody Collaboration and Licensing Deals 2016-2024

  • Report
  • 550 Pages
  • Global
From
Research Antibodies & Reagents Market by Product, Technology, Indication, Application, End User - Global Forecast 2025-2030 - Product Image

Research Antibodies & Reagents Market by Product, Technology, Indication, Application, End User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.